Tirzepatide combined with bariatric surgery investigated for severe obesity efficacy and safety

Obesity presents significant challenges due to patient heterogeneity and complex comorbidities, often making long-term management difficult with single therapeutic approaches. While bariatric surgery is currently the most effective intervention for weight loss, issues like postoperative weight regain and metabolic deterioration frequently arise. GLP-1 Receptor Agonists (GLP-1 RAs) offer distinct advantages for both weight reduction and metabolic improvement. Combining GLP-1 RAs with bariatric surgery holds promise for synergistic benefits, potentially addressing the limitations of each therapy alone and improving long-term outcomes.

This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity. The experimental arm involves Laparoscopic Sleeve Gastrectomy (LSG) combined with Tirzepatide. The Tirzepatide treatment commenced with a starting dose of 2.5 mg per week, administered subcutaneously. This adjuvant therapy continued until the completion of the 6-month postoperative period. The primary endpoints of the investigation are the efficacy and safety of this combined approach for managing severe obesity.

The provided research record describes the study's objective and methodology but does not present any findings or results. Therefore, specific data points, statistical outcomes, or quantitative measures of efficacy and safety from this investigation are not available in the given text. The study aims to evaluate the combined impact of bariatric surgery and Tirzepatide on severe obesity, but the outcomes of this evaluation are not detailed here.